|

Evexomostat Clinical Trials

1 actively recruiting trial across 1 location

Also known as: SDX-7320

Pipeline

Phase 1/2: 1

Top Sponsors

  • SynDevRx, Inc.1

Indications

  • HR+/HER2-negative Breast Cancer1
  • Metastatic Breast Cancer1
  • Breast Cancer1
  • Cancer1

Loma Linda, California1 trial

Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer

Loma Linda University Cancer Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.